/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-30 17:44:502018-01-06 17:45:08Avita Medical Appendix 4E Year Ending 30 June 2013
Alchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-30 17:44:172018-01-06 17:44:49Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets
Pharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-29 17:45:182018-01-06 17:45:40Pharmaxis Announces Delay to French Pricing for Bronchitol
Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-21 17:47:222018-01-06 17:47:54Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-21 17:33:302018-01-06 20:47:20Avita Medical Announces Completion of Enrolment in ReCell Trial for Vitiligo
Biota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-19 17:45:492018-01-06 17:46:26Biota Pharmaceuticals Announces Changes to Its Board of Directors
AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-08-08 17:46:372018-01-06 17:47:12AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis
Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK). AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-07-02 17:35:102018-01-06 17:35:43BioScience Managers Banks on Growth in Anti-Infectives Market
AmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-07-01 17:34:182018-01-06 17:35:00AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]
Avita Medical Appendix 4E Year Ending 30 June 2013
/in Avita Medical, Portfolio CompaniesAvita Medical ASX announcement link here.
Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets
/in Portfolio CompaniesAlchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]
Pharmaxis Announces Delay to French Pricing for Bronchitol
/in Destiny Pharma, Portfolio CompaniesPharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]
Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)
/in Destiny Pharma, Portfolio CompaniesPharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]
Avita Medical Announces Completion of Enrolment in ReCell Trial for Vitiligo
/in Avita MedicalAvita Medical press release link here.
Biota Pharmaceuticals Announces Changes to Its Board of Directors
/in Portfolio CompaniesBiota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]
AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis
/in Armata Pharmaceuticals, Portfolio CompaniesAmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]
BioScience Managers Banks on Growth in Anti-Infectives Market
/in BioSciences ManagersLeading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK). AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven […]
AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
/in Armata Pharmaceuticals, Portfolio CompaniesAmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]
Bioscience Managers Supports Bioxyne Decision on Transaction
/in BioSciences ManagersInternational life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]